Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
NPJ Vaccines
|
February 21, 2026
Plasmablast, memory B cell and T follicular helper cell responses after human papillomavirus vaccination: effect of dose number and age
Eunice W Kiamba, Dolapo O Ajiboye, Adedapo Olufemi Bashorun, et al.
Trials
|
September 14, 2022
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]
Ikechukwu Adigweme, Edem Akpalu, Mohammed Yisa, et al.
The Pediatric Infectious Disease Journal
|
May 27, 2020
Viral Etiology, Clinical Features and Antibiotic Use in Children <5 Years of Age in the Gambia Presenting With Influenza-like Illness
Sheikh Jarju, Khristianne Greenhalgh, Miriam Wathuo, et al.
The Lancet. Respiratory Medicine
|
June 26, 2019
Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study
Benjamin B Lindsey, Ya Jankey Jagne, Edwin P Armitage, et al.
Trials
|
September 2, 2024
Collecting and reporting adverse events in low-income settings-perspectives from vaccine trials in the Gambia
Andrew Ayi-Ashong Bruce, Ama-Onyebuchi Umesi, Adedapo Bashorun, et al.
The Lancet. Global Health
|
December 24, 2021
Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia
Adedapo O Bashorun, Mariama Badjie Hydara, Ikechukwu Adigweme, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2017
The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb
Jack Bibby, Yauba Saidu, Ama Umesi, et al.
BMJ Global Health
|
June 18, 2021
Establishing and operating a 'virtual ward' system to provide care for patients with COVID-19 at home: experience from The Gambia
Oghenebrume Wariri, Uduak Okomo, Carla Cerami, et al.
The Lancet. Microbe
|
December 9, 2021
The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24-59 months in The Gambia: a phase 4, open label, randomised, controlled trial
Chikondi Peno, Edwin P Armitage, Melanie Clerc, et al.
Plos One
|
September 22, 2025
Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol
Adedapo Olufemi Bashorun, Larry Kotei, Abdoulie F Jallow, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
NPJ Vaccines
|
February 21, 2026
Plasmablast, memory B cell and T follicular helper cell responses after human papillomavirus vaccination: effect of dose number and age
Eunice W Kiamba, Dolapo O Ajiboye, Adedapo Olufemi Bashorun, et al.
Trials
|
September 14, 2022
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]
Ikechukwu Adigweme, Edem Akpalu, Mohammed Yisa, et al.
The Pediatric Infectious Disease Journal
|
May 27, 2020
Viral Etiology, Clinical Features and Antibiotic Use in Children <5 Years of Age in the Gambia Presenting With Influenza-like Illness
Sheikh Jarju, Khristianne Greenhalgh, Miriam Wathuo, et al.
The Lancet. Respiratory Medicine
|
June 26, 2019
Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study
Benjamin B Lindsey, Ya Jankey Jagne, Edwin P Armitage, et al.
Trials
|
September 2, 2024
Collecting and reporting adverse events in low-income settings-perspectives from vaccine trials in the Gambia
Andrew Ayi-Ashong Bruce, Ama-Onyebuchi Umesi, Adedapo Bashorun, et al.
The Lancet. Global Health
|
December 24, 2021
Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia
Adedapo O Bashorun, Mariama Badjie Hydara, Ikechukwu Adigweme, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2017
The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb
Jack Bibby, Yauba Saidu, Ama Umesi, et al.
BMJ Global Health
|
June 18, 2021
Establishing and operating a 'virtual ward' system to provide care for patients with COVID-19 at home: experience from The Gambia
Oghenebrume Wariri, Uduak Okomo, Carla Cerami, et al.
The Lancet. Microbe
|
December 9, 2021
The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24-59 months in The Gambia: a phase 4, open label, randomised, controlled trial
Chikondi Peno, Edwin P Armitage, Melanie Clerc, et al.
Plos One
|
September 22, 2025
Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol
Adedapo Olufemi Bashorun, Larry Kotei, Abdoulie F Jallow, et al.
Page
of 6